ReviewCureus2026

Evolving Role of Immunotherapy in Advanced Esophageal Squamous Cell Carcinoma: Are Programmed Death-Ligand 1 (PD-L1) Cutoffs Still Relevant?

Praloy BasuPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.